Multivariate analysis for factors predicting rapid response of leukocytapheresis in patients with steroid-resistant ulcerative colitis: A multicenter prospective open-label study

Therapeutic Apheresis and Dialysis

Volumn 12, Issue 6, 2008, Pages 484-490

  Matsumoto, Takayuki ^a   Andoh, Akira ^b   Okawa, Kiyotaka ^c   Ito, Hiroaki ^d   Torii, Ayao ^e   Yoshikawa, Syusaku ^f   Nakaoka, Ryosuke ^g   Okuyama, Yusuke ^h   Oshitani, Nobuhide ⁱ   Nishishita, Masakazu ^j   Watanabe, Kenji ⁱ   Fukunaga, Ken ^a   Ohnishi, Kunio ^a   Kusaka, Takeshi ^a   Yokoyama, Yoko ^a   Sasaki, Masaya ^b   Tsujikawa, Tomoyuki ^b   Aoki, Tetsuya ^c   Kusaka, Toshihiro ^e   Takeda, Yasuhiro ^e   Umehara, Yasushi ^g   Nakamura, Shiro ⁱ   Fujiyama, Yoshihide ^b   more..

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^c OSAKA CITY GENERAL HOSPITAL   (Japan)

^d Kitano Hospital   (Japan)

^e KYOTO KATSURA HOSPITAL   (Japan)

^f Kenseikai Nara Coloproctology Center   (Japan)

^g KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h KYOTO FIRST RED CROSS HOSPITAL   (Japan)

ⁱ OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^j Nishishita Hospital of Gastroenterology   (Japan)

more..

Author keywords

Clinical activity index; Leukocytapheresis; Predictive factors; Ulcerative colitis

Indexed keywords

C REACTIVE PROTEIN; STEROID;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILL; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; FEMALE; FEVER; HEADACHE; HUMAN; LEUKAPHERESIS; LOW BACK PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; COLITIS, ULCERATIVE; DRUG RESISTANCE; FEMALE; FORECASTING; GLUCOCORTICOIDS; HUMANS; JAPAN; LEUKAPHERESIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 58149193446     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2008.00639.x     Document Type: Article

References (38)

1. Targan SR, Karp LC. Defects in mucosal immunity leading to ulcerative colitis. Immunol Rev 2005 206 : 296 305.
2. Grimm MC, Pullman WE, Bennett GM, Sullivan PJ, Pavli P, Doe WF. Direct evidence of monocyte recruitment to inflammatory bowel disease mucosa. J Gastroenterol Hepatol 1995 10 : 387 95.
3. Moertel CG, Bargen JA. A critical analysis of the use of salicylazosulfapyridine in chronic ulcerative colitis. Ann Intern Med 1959 51 : 879 89.
4. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987 317 : 1625 9.
5. Truelove SC, Witts LJ. Cortisone and corticotrophin in ulcerative colitis. BMJ 1959 1 : 387 94.
6. Meyers S, Sachar DB, Goldberg JD, Janowitz HD. Corticotropin versus hydrocortisone in the intravenous treatment of ulcerative colitis. A prospective, randomized, double-blind clinical trial. Gastroenterology 1983 85 : 351 7.
7. Mackay IR, Wall AJ, Goldstein G. Response to azathioprine in ulcerative colitis. Report of 7 cases. Am J Dig Dis 1966 11 : 536 45.
8. Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev 2000 CD000545.
9. Hibi T, Sakuraba A. Is there a role for apheresis in gastrointestinal disorders? Nat Clin Pract Gastroenterol Hepatol 2005 2 : 200 1.
10. Sawada K, Ohnishi K, Fukui S et al. Leukocytapheresis therapy, performed with leukocyte removal filter, for inflammatory bowel disease. J Gastroenterol 1995 30 : 322 9.
11. Sandborn WJ. Preliminary data on the use of apheresis in inflammatory bowel disease. Inflamm Bowel Dis 2006 12 (Suppl. 1 S15 21.
12. Sawada K, Muto T, Shimoyama T et al. Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column. Curr Pharm Des 2003 9 : 307 21.
13. Nishioka C, Aoyama N, Maekawa S et al. Leukocytapheresis therapy for steroid-naive patients with active ulcerative colitis: its clinical efficacy and adverse effects compared with those of conventional steroid therapy. J Gastroenterol Hepatol 2005 20 : 1567 71.
14. Sawada K, Kusugami K, Suzuki Y et al. Leukocytapheresis in ulcerative colitis: results of a multicenter double-blind prospective case-control study with sham apheresis as placebo treatment. Am J Gastroenterol 2005 100 : 1362 9.
15. Lichtiger S, Present DH, Kornbluth A et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994 330 : 1841 5.
16. Shibata H, Kuriyama T, Yamawaki N. Cellsorba. Ther Apher Dial 2003 7 : 44 7.
17. Andoh A, Ogawa A, Kitamura K et al. Suppression of interleukin-1beta- and tumor necrosis factor-alpha-induced inflammatory responses by leukocytapheresis therapy in patients with ulcerative colitis. J Gastroenterol 2004 39 : 1150 7.
18. Lichtiger S, Present DH. Preliminary report: cyclosporin in treatment of severe active ulcerative colitis. Lancet 1990 336 : 16 19.
19. Ogata H, Matsui T, Nakamura M et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 2006 55 : 1255 62.
20. Daperno M, Sostegni R, Scaglione N et al. Outcome of a conservative approach in severe ulcerative colitis. Dig Liver Dis 2004 36 : 21 8.
21. Shirokaze J. Leukocytapheresis using a leukocyte removal filter. Ther Apher 2002 6 : 261 6.
22. Kanai T, Hibi T, Watanabe M. The logics of leukocytapheresis as a natural biological therapy for inflammatory bowel disease. Expert Opin Biol Ther 2006 6 : 453 66.
23. Noguchi M, Hiwatashi N, Hayakawa T, Toyota T. Leukocyte removal filter-passed lymphocytes produce large amounts of interleukin-4 in immunotherapy for inflammatory bowel disease: role of bystander suppression. Ther Apher 1998 2 : 109 14.
24. Suzuki K, Sugimura K, Hasegawa K et al. Activated platelets in ulcerative colitis enhance the production of reactive oxygen species by polymorphonuclear leukocytes. Scand J Gastroenterol 2001 36 : 1301 6.
25. Hanai H, Iida T, Takeuchi K et al. Decrease of reactive-oxygen-producing granulocytes and release of IL-10 into the peripheral blood following leukocytapheresis in patients with active ulcerative colitis. World J Gastroenterol 2005 11 : 3085 90.
26. Mitsuyama K, Suzuki A, Matsumoto S et al. Diminished cytokine signalling against bacterial components in mononuclear leucocytes from ulcerative colitis patients after leukocytapheresis. Clin Exp Immunol 2005 141 : 130 40.
27. Andoh A, Tsujikawa T, Inatomi O et al. Leukocytapheresis therapy modulates circulating t cell subsets in patients with ulcerative colitis. Ther Apher Dial 2005 9 : 270 6.
28. Fukunaga K, Fukuda Y, Yokoyama Y et al. Activated platelets as a possible early marker to predict clinical efficacy of leukocytapheresis in severe ulcerative colitis patients. J Gastroenterol 2006 41 : 524 32.
29. Yagi Y, Andoh A, Inatomi O et al. Modulation of platelet aggregation responses by leukocytapheresis therapy in patients with active ulcerative colitis. J Gastroenterol 2006 41 : 540 6.
30. Kanai T, Makita S, Kawamura T et al. Extracorporeal elimination of TNF-alpha-producing CD14(dull)CD16(+) monocytes in leukocytapheresis therapy for ulcerative colitis. Inflamm Bowel Dis 2007 13 : 284 90.
31. Shimada T, Hiwatashi N, Yamazaki H, Kinouchi Y, Toyota T. Relationship between glucocorticoid receptor and response to glucocorticoid therapy in ulcerative colitis. Dis Colon Rectum 1997 40 : S54 8.
32. Farrell RJ, Kelleher D. Glucocorticoid resistance in inflammatory bowel disease. J Endocrinol 2003 178 : 339 46.
33. Fedor ME, Rubinstein A. Effects of long-term low-dose corticosteroid therapy on humoral immunity. Ann Allergy Asthma Immunol 2006 97 : 113 16.
34. Oyama Y, Craig RM, Traynor AE et al. Autologous hematopoietic stem cell transplantation in patients with refractory Crohn's disease. Gastroenterology 2005 128 : 552 63.
35. Andoh A, Bamba S, Fujiyama Y, Brittan M, Wright NA. Colonic subepithelial myofibroblasts in mucosal inflammation and repair: contribution of bone marrow-derived stem cells to the gut regenerative response. J Gastroenterol 2005 40 : 1089 99.
36. Okamoto R, Yajima T, Yamazaki M et al. Damaged epithelia regenerated by bone marrow-derived cells in the human gastrointestinal tract. Nat Med 2002 8 : 1011 17.
37. Zhang D, Sun M, Samols D, Kushner I. STAT3 participates in transcriptional activation of the C-reactive protein gene by interleukin-6. J Biol Chem 1996 271 : 9503 9.
38. Cha-Molstad H, Agrawal A, Zhang D, Samols D, Kushner I. The Rel family member P50 mediates cytokine-induced C-reactive protein expression by a novel mechanism. J Immunol 2000 165 : 4592 7.